Sourcing · Regulatory · continued

Research-use-only labelling: what it means and what it does not posts 31–60

Sourcing › Regulatory compounding research use only EMA FDA

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

n.rahimiTL28 Sep 2025#31

g.rasmussen, post #5: Worth separating research-use-only labelling as a question about the compound from research-use-only labelling as a question about the documentation. They get answered by different people and only one of them is answerable here. Go to post

Where I part company with post #27, and it is a narrow parting.

Having read the whole research-use-only labelling thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.

0 likes in reply to #5 11mo

p.amankwahTL211 Sep 2025#32

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

18 likes 11mo

l.wikstromTL213 Sep 2025 · edited#33

Research-use-only material is not approved for human use anywhere. That is a statement about the material's regulatory category rather than about its quality.

4 likes 10mo

v.nascimentoTL216 Sep 2025#34

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

This is where my knowledge stops and I would rather mark the edge than blur it.

0 likes 10mo

j.hartmannTL218 Sep 2025#35

peak_purity, post #2: Answering the research-use-only labelling question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken. Go to post

Post #31 put the caveat in the right place and I want to underline it.

Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use.

Stating my assumptions rather than smuggling them in.

26 likes in reply to #2 10mo

KnowltonTL3Regular21 Sep 2025#36

Thank you for the correction. I would rather find out here than later.

12 likes 10mo

i.coelhoTL223 Sep 2025#37

On research-use-only labelling the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.

2 likes 10mo

d.petrescuTL226 Sep 2025#38

Two questions I would want answered before drawing anything from the research-use-only labelling data above: how were the cases selected, and what happened to the ones that dropped out.

0 likes 10mo

k.agyemanTL228 Sep 2025#39

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

Happy to expand any of that if it is the useful part.

0 likes 10mo

n.torrenceTL3Regular1 Oct 2025#40

ambient_draft, post #28: Noted, and I have changed what I was going to do on the strength of it. Go to post

Post #39 is right about the mechanism and I think understates the practical bit.

Research-use-only material is not approved for human use anywhere. That is a statement about the material's regulatory category rather than about its quality.

Worth checking against a second source before it gets quoted onward.

33 likes in reply to #28 10mo

citation_indexTL2Member3 Oct 2025#41

Reporting rather than recommending, on research-use-only labelling. What happened is above. Whether it should have is a different question and not one I am qualified to answer.

2 likes in reply to #2 10mo

e.roosTL26 Oct 2025#42

weekly_pin, post #12: Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic. I would treat the number as indicative rather than as a measurement. Go to post

A label change is a regulatory event with a date and a document. Citing the document is what makes a claim about labelling checkable.

9 likes in reply to #12 10mo

s.grahameTL2Member8 Oct 2025#43

Post #40 answers the question as asked. The question underneath it is different.

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

Happy to be corrected if someone holds better data than mine.

21 likes 10mo

ar.kravchenkoTL211 Oct 2025#44

On research-use-only labelling I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

0 likes 10mo

e.dalgleishTL3Regular13 Oct 2025#45

This is the sort of exchange that makes the archive worth searching.

1 like 9mo

b.teixeiraTL215 Oct 2025 · edited#46

owen.brady, post #8: Post #6 put the caveat in the right place and I want to underline it. Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use. Go to post

The most useful reply I ever got about research-use-only labelling was a request to state my units. It sounds like pedantry and it has saved me twice.

6 likes in reply to #8 9mo

endpoint_marginTL2Member18 Oct 2025#47

Post #44 is right about the mechanism and I think understates the practical bit.

If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.

For what it is worth, the same held on the two occasions I checked.

15 likes 9mo

n.zielinskiTL220 Oct 2025#48

Coming back to post #46, because the follow-up matters more than the original answer.

What I can speak to on research-use-only labelling is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.

30 likes 9mo

n.ekstromTL2Regular22 Oct 2025#49

s.adebayo, post #13: Everything in post #9 holds. The case it does not cover is the one I have. The version of research-use-only labelling that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live. Go to post

Picking up post #48: that is the part I would want checked first.

I would call the community position on research-use-only labelling likely rather than established, and I would be comfortable defending that hedge.

0 likes in reply to #13 9mo

c.castellanosTL225 Oct 2025#50

On post #46 — agreed on the reasoning, with one qualification.

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

Reading it back, the second half matters more than the first.

3 likes 9mo

s.vogelTL227 Oct 2025#51

endpoint_margin, post #47: Post #44 is right about the mechanism and I think understates the practical bit. If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category. For what it is worth, the same held on the two occasions I checked. Go to post

An honest declaration on research-use-only labelling: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.

0 likes in reply to #47 9mo

KStephanopoulosTL3Regular29 Oct 2025#52

Knowlton, post #36: Thank you for the correction. I would rather find out here than later. Go to post

Research-use-only labelling is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.

0 likes in reply to #36 9mo

h.castellanosTL21 Nov 2025#53

On post #49 — agreed on the reasoning, with one qualification.

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

I have left out the parts I could not verify.

20 likes 9mo

footnote_entryTL3Regular3 Nov 2025#54

Picking up post #53: that is the part I would want checked first.

Trying to state the research-use-only labelling position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.

8 likes 9mo

m.ndiayeTL25 Nov 2025#55

e.dalgleish, post #45: This is the sort of exchange that makes the archive worth searching. Go to post

Coming back to post #53, because the follow-up matters more than the original answer.

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic.

Posting it because the silence on this was starting to look like agreement.

0 likes in reply to #45 9mo

bench_peakTL3Regular8 Nov 2025#56

l.wikstrom, post #33: Research-use-only material is not approved for human use anywhere. That is a statement about the material's regulatory category rather than about its quality. Go to post

Research-use-only labelling sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.

28 likes in reply to #33 9mo

t.batistaTL210 Nov 2025#57

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

Scoping that to what I have actually seen rather than what I have read.

14 likes 9mo

IsaksenTL3Regular12 Nov 2025 · edited#58

This follows post #57 rather than contradicting it.

Distinguishing three things in the research-use-only labelling discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.

5 likes 8mo

da.bakkerTL214 Nov 2025#59

I read post #57 twice before replying, because I had assumed the opposite.

Research-use-only labelling would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.

0 likes 8mo

cannula_traceTL3Regular17 Nov 2025#60

footnote_entry, post #54: Picking up post #53: that is the part I would want checked first. Trying to state the research-use-only labelling position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test. Go to post

Adding thanks rather than a view. I do not have a view worth the space.

21 likes in reply to #54 8mo